We are live on ! Find out more
VM

VV Manager Portfolio holdings

AUM $114M
1-Year Est. Return 59.16%
This Fund
S&P 500
This Quarter Est. Return
+80.39%
1 Year Est. Return
+59.16%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$114M
AUM Growth
+$25.5M
Cap. Flow
-$18.8M
Cap. Flow %
-16.46%
Top 10 Hldgs %
100%
Holding
4
New
Increased
Reduced
2
Closed

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
ALLO icon
Allogene Therapeutics
ALLO
+$17.8M
2
STRO icon
Sutro Biopharma
STRO
+$952K

Sector Composition

Rank Sector Weight
1 Healthcare 80.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ALLO icon
1
Allogene Therapeutics
ALLO
$618M
$77M 67.53%
1,798,163
-492,553
-22% -$17.8M
QTTB icon
2
Q32 Bio
QTTB
$255M
$11.7M 10.27%
42,825
STRO icon
3
Sutro Biopharma
STRO
$391M
$2.84M 2.49%
36,566
-9,920
-21% -$952K

Similar funds

VV Manager's Q2 2020 Portfolio in Review

As of Q2 2020, VV Manager held 4 positions worth $114M, up 29% from $88.5M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

VV Manager withdrew a net $18.8M in Q2 2020, reducing 2 holdings. Its largest reduction was Allogene Therapeutics, cutting an estimated $17.8M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 69% a quarter earlier.

  • VV Manager's biggest Q2 2020 reduction was Allogene Therapeutics, cutting an estimated $17.8M.
  • VV Manager's ten largest holdings make up 100% of its $114M portfolio in Q2 2020.
  • VV Manager opened 0 new positions and closed 0 in Q2 2020.
  • VV Manager's portfolio value rose 29% quarter-over-quarter to $114M.

Based on VV Manager's 13F filing for Q2 2020, filed 4 Aug 2020.